Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559519 | 1.00 | TRPV1 (0.37) | TRPV1POLBCNR1CNR2ELANE | |
| SCHEMBL5800355 | 0.93 | PTGS2 (0.36) | TRPV1POLBCNR1CNR2CYP2B6 | |
| SCHEMBL5559003 | 0.93 | EGLN1 (0.37) | TRPV1POLBCNR1CNR2GPR139 | |
| SCHEMBL5559007 | 0.93 | EGLN1 (0.37) | TRPV1POLBCNR1CNR2GPR139 | |
| SCHEMBL5559001 | 0.93 | EGLN1 (0.37) | TRPV1POLBCNR1CNR2GPR139 | |
| SCHEMBL5553952 | 0.91 | KDM4E (0.37) | ELANEGPR139MEN1KMT2A | |
| SCHEMBL5553954 | 0.91 | KDM4E (0.37) | ELANEGPR139MEN1KMT2A | |
| SCHEMBL5560440 | 0.90 | POLB (0.37) | TRPV1POLBCNR1CNR2 | |
| SCHEMBL5560445 | 0.90 | POLB (0.37) | TRPV1POLBCNR1CNR2 | |
| SCHEMBL5558899 | 0.90 | CCKBR (0.38) | TRPV1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643961-A4 | COX-2 AND FAAH INHIBITORS | MICROBIA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1643961-A2 | COX-2 AND FAAH INHIBITORS | Microbia, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050032747-A1 | COX-2 and FAAH inhibitors | POLYMER CONCEPTS TECHNOLOGIES PBY, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005002525-A2 | COX-2 AND FAAH INHIBITORS | MICROBIA, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032747-A1 | COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGS2 | TRPV1 201/4885POLB 2692/4885CNR1 18/4885 |
| US-20050234244-A1 | Synthesis of COX-2 and FAAH inhibitors | FAAH2, FAAH, PTGES2 | TRPV1 1069/4885POLB 1611/4885CNR1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.